StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

Vanda Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Vanda Pharmaceuticals's cash was $61.93M at Sep 30, 2026. For fiscal 2025 it was $84.85M, down 17.4% from the year before. Over ten years it grew -5.1% a year on average. The highest annual figure on record is $433.33M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$84.85M-17.4%
FY2024Dec 31, 2024$102.79M-24.6%
FY2023Dec 31, 2023$136.29M+0.6%
FY2022Dec 31, 2022$135.50M-68.7%
FY2021Dec 31, 2021$433.33M+17.7%
FY2020Dec 31, 2020$368.32M+17.8%
FY2019Dec 31, 2019$312.71M+21.2%
FY2018Dec 31, 2018$258.10M+79.1%
FY2017Dec 31, 2017$144.12M+1.4%
FY2016Dec 31, 2016$142.17M-1.2%
FY2015Dec 31, 2015$143.97M+10.9%
FY2014Dec 31, 2014$129.82M-0.4%
FY2013Dec 31, 2013$130.35M+8.3%
FY2012Dec 31, 2012$120.40M-19.1%
FY2011Dec 31, 2011$148.88M-24.8%
FY2010Dec 31, 2010$198.04M-3.5%
FY2009Dec 31, 2009$205.30M+425.3%
FY2008Dec 31, 2008$39.08M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$61.93M-11.6%
Q2 FY2026Jun 30, 2026$55.88M-31.0%
Q1 FY2026Mar 31, 2026$54.03M-51.7%
Q4 FY2025Dec 31, 2025$84.85M-17.4%
Q3 FY2025Sep 30, 2025$70.02M-30.3%
Q2 FY2025Jun 30, 2025$80.98M-21.3%
Q1 FY2025Mar 31, 2025$111.80M-10.7%
Q4 FY2024Dec 31, 2024$102.79M-24.6%
Q3 FY2024Sep 30, 2024$100.50M-45.1%
Q2 FY2024Jun 30, 2024$102.95M-31.4%
Q1 FY2024Mar 31, 2024$125.16M-64.7%
Q4 FY2023Dec 31, 2023$136.29M+0.6%
Q3 FY2023Sep 30, 2023$183.19M+270.8%
Q2 FY2023Jun 30, 2023$150.03M-66.0%
Q1 FY2023Mar 31, 2023$354.17M-18.6%
Q4 FY2022Dec 31, 2022$135.50M-68.7%
Q3 FY2022Sep 30, 2022$49.40M-87.8%
Q2 FY2022Jun 30, 2022$440.86M+11.2%
Q1 FY2022Mar 31, 2022$435.18M+15.1%
Q4 FY2021Dec 31, 2021$433.33M+17.7%
Q3 FY2021Sep 30, 2021$405.97M+16.5%
Q2 FY2021Jun 30, 2021$396.49M+16.7%
Q1 FY2021Mar 31, 2021$378.16M+21.1%
Q4 FY2020Dec 31, 2020$368.32M+17.8%
Q3 FY2020Sep 30, 2020$348.55M+46.6%
Q2 FY2020Jun 30, 2020$339.85M+21.3%
Q1 FY2020Mar 31, 2020$312.33M+16.6%
Q4 FY2019Dec 31, 2019$312.71M+21.2%
Q3 FY2019Sep 30, 2019$237.79M-1.2%
Q2 FY2019Jun 30, 2019$280.16M+21.2%
Q1 FY2019Mar 31, 2019$267.84M+7.6%
Q4 FY2018Dec 31, 2018$258.10M+79.1%
Q3 FY2018Sep 30, 2018$240.58M+71.0%
Q2 FY2018Jun 30, 2018$231.22M+67.6%
Q1 FY2018Mar 31, 2018$248.83M+79.6%
Q4 FY2017Dec 31, 2017$144.12M+1.4%
Q3 FY2017Sep 30, 2017$140.71M–
Q2 FY2017Jun 30, 2017$137.95M–
Q1 FY2017Mar 31, 2017$138.59M–
Q4 FY2016Dec 31, 2016$142.17M–

More Vanda Pharmaceuticals figures

See a number that looks wrong?